Core Insights - Incyte reported $1.22 billion in revenue for Q2 2025, a 16.5% year-over-year increase, with an EPS of $1.57 compared to -$1.82 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company’s revenue and EPS surprises were +5.56% and +12.95% respectively, indicating stronger performance than analysts anticipated [1] Revenue Breakdown - Product royalty revenues reached $151.12 million, surpassing the estimated $145.98 million, reflecting a 10.2% increase year-over-year [4] - Net product revenues for Iclusig were $32.73 million, exceeding the $28.99 million estimate, marking a 21.8% year-over-year growth [4] - Total net product revenues amounted to $1.06 billion, above the $985.29 million estimate, showing a 16.9% increase year-over-year [4] - Net product revenues for Pemazyre were $22.19 million, compared to the $20.24 million estimate, representing a 9.5% year-over-year change [4] - Net product revenues for Minjuvi/Monjuvi were $31.13 million, slightly below the $34.25 million estimate, with a minimal year-over-year change of 0.1% [4] - Net product revenues for Opzelura reached $164.5 million, exceeding the $148.56 million estimate, reflecting a significant 35.2% year-over-year increase [4] - Net product revenues for Jakafi were $763.79 million, surpassing the $744.1 million estimate, with an 8.2% year-over-year growth [4] - Net product revenues for Zynyz were $8.92 million, significantly above the $2.73 million estimate, indicating a remarkable 1270.4% year-over-year increase [4] - Royalty revenues for Olumiant were $33.48 million, slightly below the $33.57 million estimate, with a 5.6% year-over-year increase [4] - Royalty revenues for Tabrecta were $6.63 million, below the $6.88 million estimate, reflecting a 25.2% year-over-year increase [4] - Royalty revenues for Jakavi were $109.71 million, exceeding the $103.35 million estimate, with a 10.5% year-over-year change [4] - Net product revenues for Niktimvo were $36.15 million, significantly above the $20.33 million estimate [4] Stock Performance - Incyte's shares returned +3% over the past month, compared to the Zacks S&P 500 composite's +3.6% change, indicating a performance in line with the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]

Core Insights - Incyte reported $1.05 billion in revenue for Q1 2025, a 19.5% year-over-year increase, with an EPS of $1.16 compared to $0.64 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.01 billion by 4.66%, and the EPS also surpassed the consensus estimate of $1.01 by 14.85% [1] Revenue Performance - Net product revenues for Pemazyre were $18.44 million, below the average estimate of $21.62 million, representing a 4.3% year-over-year increase [4] - Total product revenues reached $922.27 million, exceeding the average estimate of $876.70 million, with a year-over-year change of 26.4% [4] - Iclusig generated $29.54 million in net product revenues, slightly above the average estimate of $28.67 million, but a 2.6% decrease year-over-year [4] - Minjuvi/Monjuvi reported $29.55 million, below the average estimate of $33.43 million, with a year-over-year increase of 23.8% [4] - Opzelura's net product revenues were $118.71 million, below the average estimate of $126.95 million, reflecting a 38.5% year-over-year increase [4] - Jakafi generated $709.41 million, surpassing the average estimate of $661.10 million, with a 24.1% year-over-year increase [4] - Zynyz reported $3.01 million, exceeding the average estimate of $1.92 million [4] Royalty Revenues - Jakavi's royalty revenues were $92.15 million, below the average estimate of $97.41 million, with a 2.9% year-over-year increase [4] - Total product royalty revenues reached $130.62 million, below the average estimate of $139.49 million, reflecting a 3.7% year-over-year increase [4] - Olumiant's royalty revenues were $30.80 million, below the average estimate of $34.90 million, with a 0.7% year-over-year change [4] - Tabrecta generated $6.41 million, exceeding the average estimate of $5.93 million, with a 22.5% year-over-year increase [4] Stock Performance - Incyte's shares returned -1.7% over the past month, compared to the S&P 500 composite's -0.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]